4.6 Article

Targeting Wnt/tenascin C-mediated cross talk between pancreatic cancer cells and stellate cells via activation of the metastasis suppressor NDRG1

Journal

JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 298, Issue 3, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.jbc.2022.101608

Keywords

-

Funding

  1. Avner Pancreatic Cancer Foundation 2018 Innovation grant
  2. National Health and Medical Research Council (NHMRC) [APP1160968]
  3. Cancer Institute of NSW (CINSW) [2016/0RFlOl]
  4. University of Sydney
  5. National Health and Medical Research Council RD Wright Fellowship [APP1140447]
  6. CINSW Career Development Fellowship [CDF171126]
  7. University of Sydney Equity Fellowship
  8. University of Sydney International Scholarship (USydIS)
  9. Cancer Institute NSW Career Development Fellowship [CDF171147]
  10. Pankind Foundation
  11. NHMRC [1062607, 1159596, APP1144829, APP1128152, APP1144456]
  12. Avner Pancreatic Cancer Foundation
  13. National Health and Medical Research Council of Australia [1062607, 1159596] Funding Source: NHMRC

Ask authors/readers for more resources

A major obstacle to successful pancreatic cancer treatment is the stroma surrounding the tumor, which secretes growth factors and cytokines that promote cancer progression. This study demonstrates that targeting the metastasis suppressor NDRG1 can inhibit the interaction between pancreatic cancer cells and pancreatic stellate cells mediated by Wnt and TnC, thereby inhibiting tumor progression.
A major barrier to successful pancreatic cancer (PC) treatment is the surrounding stroma, which secretes growth factors/cytokines that promote PC progression. Wnt and tenascin C (TnC) are key ligands secreted by stromal pancreatic stellate cells (PSCs) that then act on PC cells in a paracrine manner to activate the oncogenic beta-catenin and YAP/TAZ signaling pathways. Therefore, therapies targeting oncogenic Wnt/TnC cross talk between PC cells and PSCs constitute a promising new therapeutic approach for PC treatment. The metastasis suppressor N-myc downstream regulated gene-1 (NDRG1) inhibits tumor progression and metastasis in numerous cancers, including PC. We demonstrate herein that targeting NDRG1 using the clinically trialed anticancer agent di-2-pyridylketone-4-cyclohexyl-4-methyl-3thiosemicarbazone (DpC) inhibited Wnt/TnC-mediated interactions between PC cells and the surrounding PSCs. Mechanistically, NDRG1 and DpC markedly inhibit secretion of Wnt3a and TnC by PSCs, while also attenuating Wnt/beta- catenin and YAP/TAZ activation and downstream signaling in PC cells. This antioncogenic activity was mediated by direct inhibition of beta-catenin and YAP/TAZ nuclear localization and by increasing the Wnt inhibitor, DKK1. Expression of NDRG1 also inhibited transforming growth factor (TGF)-beta secretion by PC cells, a key mechanism by which PC cells activate PSCs. Using an in vivo orthotopic PC mouse model, we show DpC downregulated beta-catenin, TnC, and YAP/TAZ, while potently increasing NDRG1 expression in PC tumors. We conclude that NDRG1 and DpC inhibit Wnt/TnC-mediated interactions between PC cells and PSCs. These results further illuminate the antioncogenic mechanism of NDRG1 and the potential of targeting this metastasis suppressor to overcome the oncogenic effects of the PC-PSC interaction.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available